United States: Federal Circuit Provides Additional Guidance In Reversing Holding Of Patent-Ineligibility Of Biotech Invention

Although it is not yet a bright line, the Federal Circuit has considerably decreased the fuzziness of the distinction between patent-eligible and patent-ineligible inventions, at least where the exception to 35 U.S.C. § 101 is a law of nature. In Rapid Litigation Management Ltd. v. Cellzdirect, Inc., Appeal No. 2015-1570 (Fed. Cir. July 5, 2016), the Federal Circuit reversed the district court's holding of invalidity under § 101, ruling that the district court erred in applying both step 1 and step 2 of the Supreme Court's framework for determining patent eligibility. See Alice Corp. v. CLS Bank Int'l, 134 S. Ct. 2347, 2355 (2014).

The district court held that the patent in suit is directed to a law of nature—that hepatocytes, a type of liver cell, are capable of surviving multiple freeze-thaw cycles—and that the patented process lacks the requisite inventive concept. Hepatocytes have a number of uses, such as for investigating how drugs may be metabolized by the liver or measuring a drug's effect on liver biology, but their availability is limited and their life span is short. The prior art disclosed freezing hepatocytes ("cryopreservation"), thawing them when needed, and recovering the viable cells using density gradient fractionation, but persons of ordinary skill in the art understood that that process could damage the cells and lead to poor recoveries of viable cells. Moreover, pooled samples from multiple donors, desirable to create a collection of cells approximating average liver cells, could be created only by accumulating and freezing cells from single donors and then thawing and combining them for immediate use. Those skilled in the art believed that cryopreservation could be employed only once, and cryopreservation could damage cells, which severely limited the creation of pooled cells.

The inventors' discovery was a law of nature: that a fraction of hepatocytes can survive multiple freeze-thaw cycles. Based on that discovery, the inventors claimed a method of producing a collection of hepatocytes by subjecting previously frozen and thawed cells to fractionation to separate and recover viable cells, and refreezing the viable cells, which, after being thawed again, exhibit 70 percent viability. Thus, claim 1 recites:

  1. A method of producing a desired preparation of multi-cryopreserved hepatocytes, said hepatocytes being capable of being frozen and thawed at least two times, and in which greater than 70% of the hepatocytes of said preparation are viable after the final thaw, said method comprising:

(A) subjecting hepatocytes that have been frozen and thawed to density gradient fractionation to separate viable hepatocytes from nonviable hepatocytes,

(B) recovering the separated viable hepatocytes, and

(C) cryopreserving the recovered viable hepatocytes to thereby form said desired preparation of hepatocytes without requiring a density gradient step after thawing the hepatocytes for the second time, wherein the hepatocytes are not plated between the first and second cryopreservations, and wherein greater than 70% of the hepatocytes of said preparation are viable after the final thaw.

Claim 5 depends on claim 1 and limits the "preparation" to a pooled preparation of cells from multiple sources.

The patented process enables the production of cells that can be thawed later with sufficient viability, and for the first time permits refreezing of pooled hepatocyte preparations for later use. The district court, however, invalidated the claims under § 101 as directed to a law of nature (step 1) and as simply reapplying "a well-understood freezing process" (step 2).

The Federal Circuit accorded no deference to the district court, noting that patent eligibility is a question of law. Its reasoning in reversing the district court on both steps 1 and 2 reveals important factors in determination of the issue.

One factor, applicable to all of the exceptions to § 101, is whether the claimed invention preempts the natural phenomena, abstract idea, or law of nature. "The concern underlying these judicial exclusions is that 'patent law not inhibit further discovery by improperly tying up the future use of these building blocks of human ingenuity.'" Slip op. at 7 (quoting Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1301 (2012)). Regarding step 1, the court emphasized that the exception applies only if the claims are "directed to" a patent-ineligible concept. The court reasoned that the patented claims on appeal are directed to a laboratory technique for preserving hepatocytes, not the law of nature, i.e. the ability of hepatocytes to survive multiple freeze-thaw cycles. Instead, the inventors "employed their natural discovery to create a new and improved way of preserving hepatocyte cells for later use." Slip op. at 9. Moreover, the court relied on the district court's finding that the patent in suit did not preempt the natural law as confirming its conclusion under step 1. Slip op. at 16-17. Thus, whether a claim is "directed to" a patent-ineligible concept appears to be closely related to whether it preempts the concept.

The court distinguished cases it had held to have patent-ineligible claims. Those cases, the court said, had claims that required merely observing or identifying the ineligible concept itself. Id. In Genetic Techs., Ltd. v. Merial L.L.C., 18 F.3d 1369, 1373-74 (Fed. Cir. 2016), the court explained, the patent claimed detecting a coating region of DNA based on its relationship to non-coating regions, the relationship constituting a law of nature. Consequently, "the claim amounted to nothing other than identifying 'information about a patient's natural genetic makeup.'" Slip op. at 9 (quoting Genetic Techs. at 1375). Similarly, the court explained that in Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1373-74 (Fed. Cir. 2015), cert. denied, No. 15-1102, 2016 WL 1117246 (June 27, 2016), the patent-ineligible claims recited methods for detecting paternally inherited cffDNA in the blood of a pregnant female, and because the existence of cffDNA is a natural phenomenon, detecting it was "claiming the natural phenomena itself." Slip op. at 9. And regarding the claims in In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 774 F.3d 755, 761-62 (Fed. Cir. 2014), the court reasoned that "comparing two sequences to detect alterations is a patent-ineligible 'abstract mental process.'" Slip op. at 9 (quoting id. at 763) (emphasis added). The "essence of the whole" in each of those cases, according to the court, was a patent-ineligible concept. Slip op. at 9-10.

By contrast, the court noted that the patent claims before it were "directed to a new and useful method of preserving hepatocyte cells," not just the ability of the cells to survive multiple freeze-thaw cycles. Slip op. at 10 (emphasis added). The patent claims

are like thousands of others that recite processes to achieve a desired outcome, e.g., methods of producing things, or methods of treating disease. That one way of describing the process is to describe the natural ability of the subject matter to undergo the process does not make the claim "directed to" that natural ability. If that were so, we would find patent-ineligible methods of, say, producing a new compound (as directed to the individual components' ability to combine to form the new compound) . . . .

Slip op. at 10.

Regarding the pooling of cells required by claim 5, the court relied on the difference between product and process claims. The court distinguished Funk Bros. Co. v. Kalo Innoculant Co., 333 U.S. 127 (1948), where the Supreme Court held that a mixture of different bacterial species was not patent eligible because each species in the mixture performed in its natural way, by observing that Funk Bros. involved product claims while in the case before it "the claims are directed to a new and useful process of creating that pool, not to the pool itself." Slip op. at 11. The court noted that in Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013), the Supreme Court similarly observed that that case held composition claims to isolated DNA ineligible and that "[h]ad Myriad created an innovative method of manipulating genes . . . it could have possibly sought a method patent." Slip op. at 11 (quoting Myriad, 133 S. Ct. at 2119-20) (emphasis added). In the case before it, the Federal Circuit reasoned, "the inventors developed an innovative method of manipulating hepatocytes . . . ." Slip op. at 11 (emphasis added).

The court concluded regarding step 1 by emphasizing that mere involvement of a patent-ineligible concept does not invoke the prohibition of step 1 if the claim is not "directed to" the patent-ineligible concept. The patent in suit, the court reasoned, "does not simply claim hepatocytes' ability to survive multiple freeze-thaw cycles," but "instead claims a 'method of producing a desired preparation of multi-cryopreserved hepatocytes.'" Slip op. at 13 (quoting claim 1).

Having held that the district court erred in its holding regarding step 1, the Federal Circuit could of course have stopped. Perhaps to provide additional guidance in this developing area of the law, however, the court proceeded to explain why the district court also erred regarding step 2. The Federal Circuit reasoned that the claimed process improved an existing technological process sufficiently to transform it into an inventive application of what the defendants alleged was a patent-ineligible concept. The claims "recite an improved process for preserving hepatocytes for later use. The benefits of the improved process over the prior art methods are significant. . . . The claimed method is patent eligible because it applies the discovery that hepatocytes can be twice frozen to achieve a new and useful preservation process." Slip op. at 13-14.

The court rejected the argument that because each claimed step was known individually, the combination of steps did not make the claim patent eligible. It explained, "in examining claims under step two, we must view them as a whole, considering their elements 'both individually and as an ordered combination.'" Slip op. at 14 (quoting Alice, 134 S. Ct. at 2355) (internal quotations and citation omitted). The court reasoned that although freezing and thawing were well known, "[r]epeating a step that the art taught should be performed only once can hardly be considered routine or conventional. This is true even though it was the inventor's [sic] discovery of something natural that led them to do so. . . . To require something more at step two would be to discount the human ingenuity that comes from applying a natural discovery in a way that achieves a 'new and useful end.'" Slip op. at 15-16 (quoting Alice, 134 S. Ct. at 2354).

Finally, the court made two important observations. First, "patent-eligibility does not turn on ease of execution or obviousness of application" once the natural law was discovered. "Those are questions that are examined under separate provisions of the Patent Act." Slip op. at 16 (citing Mayo, 132 S. Ct. at 1304). Second, the court relied on the district court's finding that the patent in suit did not preempt the natural law and that the defendant had already managed to design around the patent. "[W]hile pre-emption is not the test for determining patent-eligibility . . ., it is certainly the 'concern that undergirds . . . § 101 jurisprudence,' Alice, 134 S. Ct. at 2358." Slip op. at 16. As noted above, the court asserted that the lack of preemption confirmed its conclusion that the patent is not "directed to" a patent-ineligible law of nature. Slip op. at 16-17.

In summary, key points from the case appear to be:

  1. Claims that do not preempt one of the exceptions to § 101 tend to be patent eligible.
  2. Mere involvement of a law of nature, and perhaps natural phenomena or abstract ideas, does not render a claimed invention patent ineligible unless the claims are "directed to" one of those exception to § 101. A claim that simply recites a law of nature is likely "directed to" that law of nature.
  3. A claim that applies a law of nature or abstract mental process merely by reciting a step of observing, identifying, detecting, or comparing may be held to be "directed to" the law of nature or abstract mental process.
  4. But a claimed method that goes further and applies a law of nature to achieve a better way of producing something or treating disease will likely qualify for patent protection.
  5. In applying step 2, that all of the claimed steps individually were well known does not disqualify a process from patenting if the combination of steps is new and therefore not routine and conventional.
  6. That a patented process would have been obvious once the law of nature was discovered does not render the process patent ineligible, but rather depends on application of § 103.
  7. Preemption vel non, although not conclusive, is an important factor in determining patent eligibility.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.